233 related articles for article (PubMed ID: 34805377)
1. Hypertriglyceridaemia: contemporary management of a neglected cardiovascular risk factor.
Khan TZ; Schatz U; Bornstein SR; Barbir M
Glob Cardiol Sci Pract; 2021 Oct; 2021(3):e202119. PubMed ID: 34805377
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap.
Parhofer KG; Chapman MJ; Nordestgaard BG
Eur Heart J Suppl; 2020 Oct; 22(Suppl J):J21-J33. PubMed ID: 33061865
[TBL] [Abstract][Full Text] [Related]
4. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.
Zambon A; Pirillo A; Zambon S; Norata GD; Catapano AL
Curr Atheroscler Rep; 2020 Oct; 22(12):74. PubMed ID: 33009961
[TBL] [Abstract][Full Text] [Related]
5. How to Handle Elevated Triglycerides: Life after PROMINENT.
Pirillo A; Catapano AL
Curr Atheroscler Rep; 2023 Dec; 25(12):921-929. PubMed ID: 38114852
[TBL] [Abstract][Full Text] [Related]
6. Demystifying the management of hypertriglyceridaemia.
Watts GF; Ooi EM; Chan DC
Nat Rev Cardiol; 2013 Nov; 10(11):648-61. PubMed ID: 24060958
[TBL] [Abstract][Full Text] [Related]
7. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
[TBL] [Abstract][Full Text] [Related]
8. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
9. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies.
Lawler PR; Kotrri G; Koh M; Goodman SG; Farkouh ME; Lee DS; Austin PC; Udell JA; Ko DT
Eur Heart J; 2020 Jan; 41(1):86-94. PubMed ID: 31733058
[TBL] [Abstract][Full Text] [Related]
10. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
Hernandez P; Passi N; Modarressi T; Kulkarni V; Soni M; Burke F; Bajaj A; Soffer D
Curr Atheroscler Rep; 2021 Sep; 23(11):72. PubMed ID: 34515873
[TBL] [Abstract][Full Text] [Related]
11. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
Boden WE; Bhatt DL; Toth PP; Ray KK; Chapman MJ; Lüscher TF
Eur Heart J; 2020 Jun; 41(24):2304-2312. PubMed ID: 31872245
[TBL] [Abstract][Full Text] [Related]
12. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
13. Investigation and management of hypertriglyceridaemia.
Ferns G; Keti V; Griffin B
J Clin Pathol; 2008 Nov; 61(11):1174-83. PubMed ID: 18955574
[TBL] [Abstract][Full Text] [Related]
14. Hypertriglyceridaemia and risk of coronary artery disease.
Reiner Ž
Nat Rev Cardiol; 2017 Jul; 14(7):401-411. PubMed ID: 28300080
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
16. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
17. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
[TBL] [Abstract][Full Text] [Related]
18. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline.
Xu J; Ashjian E
J Pharm Pract; 2023 Jun; 36(3):650-661. PubMed ID: 34720008
[TBL] [Abstract][Full Text] [Related]
20. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
